Figure 4.
Reduced disease progression in NSG Mpl−/− mice. Eμ-myc 5849 (104 P1) tumor cells were injected IV into NSG and NSG Mpl−/− mice 14 days before analysis. (A) Platelet count, (C) WBC count, (E) lymphocyte count, and (G) spleen weight. Mean ± SEM. n = 3 to 5 mice per genotype (Eμ-myc transplant). n = 10 to 14 mice per genotype (without transplantation). Spleen (n = 3-6 mice without transplantation per genotype). Human GRANTA (2 × 106) tumor cells were injected intraperitoneally into NSG and NSG Mpl−/− mice 23 days before analysis. (B) Platelet count, (D) WBC count, (F) lymphocyte count, and (H) spleen weight. Mean ± SEM. n = 8 to 11 mice per genotype (GRANTA transplant). n = 3 to 6 mice per genotype (without transplantation). Male and female mice. Each symbol represents an individual mouse. One-way ANOVA with Tukey multiple comparison test were performed on data that passed the Shapiro-Wilks normality test, panels A, C, D, F, and G. Student unpaired t test with Mann Whitney U test were performed for data that did not pass the normality test, panels B, E, and H. ∗P < .05, ∗∗P < .005, ∗∗∗P < .001, ∗∗∗∗P < .0001.